1.Allergic patients due to carbamazepine in BachMai Hospital (1991- 1998).
Journal of Medical and Pharmaceutical Information 2000;(4):32-35
A study on 24 allergic patients due to carbamazepine (1991- 1998) was performed at Bach mai Hospital. Results showed that: - The first signs of allergy appear late(11.37+4.56 days). - Main clinical symptoms of allergy are necrosis at natural cavities, erythema, fever. - The main clinical form of allergy is Stevens-Johnson syndrome (79.16%). - Elevated ESR, SGOT, SGPT are the main changes in tests. - It takes a long time to treat allergic patients due to carbamazepine (12.61+35days) - Glucocorticoid, dimedrol, glucose and ascorbic acid solution are the common medications.
Hypersensitivity
;
carbamazepine
2.Combined use of carbamazepine and haloperidol in treatment-resistant schizophrenics: A double-blind, placebo-controlled study.
Chul Eung KIM ; Kyoo Seob HA ; Dae Yeob KANG ; Chung Han YOON ; Yong Sik KIM
Journal of Korean Neuropsychiatric Association 1993;32(3):400-406
No abstract available.
Carbamazepine*
;
Haloperidol*
3.Usefulness of Extracorporeal Treatment for Combined Intoxication with Controlled-Release Carbamazepine and Topiramate.
Minjung KIM ; Oh Young KWON ; Do Hyung KIM ; Sangkyeong YOO ; Dong Jun PARK ; Heejeong JEONG ; Seungnam SON ; Soo Kyoung KIM ; Heeyoung KANG ; Ki Jong PARK ; Nack Cheon CHOI ; Byenghoon LIM
Journal of the Korean Neurological Association 2016;34(1):37-40
Controlled-release carbamazepine (CBZ) could be more harmful than the regular form in special situations due to their respective biochemical characteristics. When primary treatment is not effective in acute intoxication, extracorporeal treatment (ECTR) could be an option. We recently applied ECTR to a patient with combined intoxication of topiramate and controlled-release CBZ who deteriorated despite receiving primary treatment. The patient improved after administering ECTR. Early ECTR intervention may be beneficial for the treatment of CBZ intoxication, especially of the controlled-release form.
Carbamazepine*
;
Extracorporeal Circulation
;
Humans
4.Electrical status epilepticus during sleep in a male Filipino with rare nonsense mutation variant of Sotos Syndrome on Carbamazepine Monotherapy
Jeffrey I. Lappay ; Benilda C. Sanchez-Gan ; Michelle E. Abadingo
Acta Medica Philippina 2024;58(4):83-87
Electrical status epilepticus during sleep (ESES) is an electrographic pattern associated with specific genetic disorders, brain malformations, and use of some antiseizure medications. This case report aims to present the management of ESES in Sotos syndrome (SoS) on carbamazepine.
A nine-year-old Filipino male with clinical features suggestive of overgrowth syndrome presented with febrile seizure at one year old. Cranial imaging showed cavum septum pellucidum, corpus callosal dysgenesis, and ventriculomegaly. He was on carbamazepine monotherapy starting at three years old. A near continuous diffuse spike–wave discharges in slow wave sleep was recorded at nine years old hence shifted to valproic acid. Follow-up study showed focal epileptiform discharges during sleep with disappearance of ESES. Next generation sequencing tested positive for rare nonsense mutation of nuclear receptor binding set-domain protein 1 confirming the diagnosis of SoS.
Advanced molecular genetics contributed to determination of ESES etiologies. To date, this is the first documented case of SoS developing ESES. Whether an inherent genetic predisposition or drug-induced, we recommend the avoidance of carbamazepine and use of valproic acid as first-line therapy.
Sotos Syndrome
;
Carbamazepine
5.Cataract Following Long-term Use of Carbamazepine in Young Adult.
Kyung Il PARK ; Jae Myun CHUNG
Journal of the Korean Neurological Association 2010;28(2):127-128
No abstract available.
Carbamazepine
;
Cataract
;
Humans
;
Young Adult
6.Comparative Add-on Trial of Vigabatrin and Valproic Acid on Intractable Partial Seizures with Carbamazepine Monotherapy.
Sang Kun LEE ; Hyun Woo NAM ; In Jin CHANG
Journal of the Korean Neurological Association 1997;15(4):754-761
PURPOSE: To evaluate the efficacy of vigabatrin and valproic acid add-on therapy in the treatment of uncontrolled partial-onset seizures through randomized active controlled parallel-group trial. METHODS: Criteria for entry included a requirement for three or more partial seizures per month despite the blood level of carbamazepine was within therapeutic range. During the 56-day baseline period, patients had at least 6 partial onset seizures. Vigabatrin or valproic acid were administered as the second drug in a randomized fashion. RESULTS: Forty one patients completed the trial(21 for vigabatrin, 20 for valproic acid). There is no statistically significant difference in age, age at onset, baseline seizure frequency, dose of carbamazepine, and serum level of carbamazepine between two groups. Two patients of vigabatrin-treated group and three patients of valproic acid treated group were dropped out because of side effects. The mean vigabatrin and valproic acid does were 2809 and 1490 mg, respectively. The percentage of patients achieving at least a 50% reduction in seizure frequency at the end of 8-week of add-on trial was 62% among vigabatrin-treated patients and was 50% for patients who received valproic acid(not statistically different). There was no significant difference in seizure reduction, percent seizure reduction, and truncated percent seizure reduction between two groups. The side effects were mild and transient neurotoxic symptoms in the patients who completed the trial(5 patients for vigabatrin, 10 patients for valproic acid). CONCLUSIONS: This trial indicates that vigabatrin and valproic acid are safe and effective in the treatment of intractable partial-onset seizures. The efficacy of vigabatrin as a new add-on antiepileptic drug is comparable to the previous valproic acid carbamazepine combination in the sense of seizure reduction and maybe even superior to that in the consideration of side effects
Carbamazepine*
;
Humans
;
Seizures*
;
Valproic Acid*
;
Vigabatrin*
7.The Effect of Carbamazepine-Controlled Release on the Congnitive Function.
Kab Jin KIM ; Jae Woo KIM ; Sang Ho KIM ; Kyung Min HA ; Sang Kun LEE
Journal of the Korean Neurological Association 1995;13(2):224-232
We evaluated the effect of carbamazepine-controlled release (CR) on the cognitive function. By using monotherapy study, we investigated the effects of carbamazepine on cognitive function in 10 epileptic patients and 17 normal controls. The evaluations were conducted before and one and six months after therapy using neuropsychological batteries(BUSCHKE SELECTIVE REMINDING TEST BSRT, REY OSTERRIETH COMPLEX FIGURE TEST ROCFT, CONCENTRATION ENDURANCE TEST d2 test, REY VISUAL DESIGN LEARNING TEST RVDLT, FINGER TAPPING TEST). In the patients treated with carbamazepine-CR monotherapy, follow up studies were made in one and six months later, respectively. It was found that the cognitive function determined in the three tests(consistent long-term retrieval : one item of BSRT, d2 test, and ROCFT : P 0.05). The mean anticonvulsant blood levels on the day of cognitive function tests were 6.48mg/ml (SD=l. 87) and 6.53mg /ml (SD=l.97) in one and six months respectively. This study showed carbamazepine-CR monotherapy had an adverse effect on the cognitive function.
Carbamazepine
;
Fingers
;
Follow-Up Studies
;
Humans
;
Learning
8.A Case of Stevens-Johnson Syndrome in a Hypoxic Brain Injury Patient Treated with Carbamazepine.
Yong Ku KIM ; Heon Jeong LEE ; Chang Su HAN ; Min Soo LEE ; Dong Il KWAK
Journal of Korean Neuropsychiatric Association 1997;36(4):770-773
Although carbamazepine is being widely used in treatment of a variety of psychiatric disorders, it has some serious potential risks, including Stevens-johnson syndrome. Authors experienced in consultation a case of Stevens-johnson syndrome due to usage of carbamazepine. The patient was treated with carbamazepine to control for aggressive behavior after a hypoxic brain damage. Authors report a case of Stevens-johnson syndrome due to carbamazepine and also reviews related articles.
Brain Injuries*
;
Brain*
;
Carbamazepine*
;
Humans
;
Hypoxia, Brain
;
Stevens-Johnson Syndrome*
9.Stevens-Johnson Syndrome Induced by Carbamazepine Treatment in a Patient Who Previously Had Carbamazepine Induced Pruritus: A Case Report.
Hyun Min BAE ; Yoo Jung PARK ; Young Hoon KIM ; Dong Eon MOON
The Korean Journal of Pain 2013;26(1):80-83
Stevens-Johnson syndrome (SJS) is a rare but life-threatening skin reaction disease and carbamazepine is one of its most common causes. We report a case of SJS secondary to carbamazepine in a patient with previous pruritus due to carbamazepine which was given for treatment of trigeminal neuralgia. We would like to caution all providers that carbamazepine readministration should be avoided in the patient with a previous history of SJS or adverse skin reaction. In addition, we strongly recommend gradual titration when initiating treatment with carbamazepine.
Carbamazepine
;
Humans
;
Pruritus
;
Skin
;
Stevens-Johnson Syndrome
;
Trigeminal Neuralgia
10.The Effects of Antiepileptic Drugs on Balance in Older People.
Journal of the Korean Neurological Association 2008;26(3):186-193
BACKGROUND: The purpose of this study was to quantitatively assess the subclinical balance dysfunction in elderly people taking antiepileptic drugs. METHODS: We recruited sixty-three patients who were at least 50 years old, without complaint of dizziness or imbalance, and on a stable dose of carbamazepine, lamotrigine or levetiracetam. Their balance scores were compared with those of newly diagnosed untreated age- and sex-matched epilepsy patients (n=21). All the subjects underwent balance measurements that included an activities-specific balance confidence scale, quantitative caloric and rotational chair testing and posturography. The spectral frequency analysis of body sway while standing upright was also investigated. Sensory organization (SOT) and motor control tests were done by computerized dynamic posturography (CDP). RESULTS: The sway distance and area of center of pressure significantly increased in the patients treated with carbamazepine. Spectral frequency analysis of this group showed a significantly increased spectral power at low and middle frequencies on the antero-posterior (Y) plane and at low frequencies on the lateral (X) plane. CDP showed no significant differences in SOT results among the groups. However, motor control test revealed increased latencies and slowed adaptations in the carbamazepine group. CONCLUSIONS: These findings suggest that newer drugs such as lamotrigine or levetiracetam may induce less disequilibrium than carbamazepine in older people on monotherapy for epilepsy. The disturbance is likely related to slowed central postural reflexes.
Aged
;
Anticonvulsants
;
Carbamazepine
;
Cytidine Diphosphate
;
Dizziness
;
Epilepsy
;
Humans
;
Piracetam
;
Triazines